CompletedPhase 2NCT02899195
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PrECOG, LLC.
- Principal Investigator
- Patrick Forde, MDJohn Hopkins
- Intervention
- Durvalumab(drug)
- Enrollment
- 55 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2023
Study locations (20)
- University San Diego Moores Cancer Center, La Jolla, California, United States
- Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
- Stanford Cancer Institute, Stanford, California, United States
- University of Colorado, Anschutz Cancer Pavilion, Aurora, Colorado, United States
- University of Miami Hospital, Miami, Florida, United States
- Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- NorthShore University HealthSystem, Evanston, Illinois, United States
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
- St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States
- Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States
- Washington University in St Louis, St Louis, Missouri, United States
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- New York University Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- +5 more locations on ClinicalTrials.gov
Collaborators
AstraZeneca
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02899195 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited